Quantification of the spread of SARS-CoV-2 variant B.1.1.7 in Switzerland

Background: In December 2020, the United Kingdom (UK) reported a SARS-CoV-2 Variant of Concern (VoC) which is now named B.1.1.7. Based on initial data from the UK and later data from other countries, this variant was estimated to have a transmission fitness advantage of around 40–80 % (Volz et al.,...

Full description

Bibliographic Details
Main Authors: Chaoran Chen, Sarah Ann Nadeau, Ivan Topolsky, Marc Manceau, Jana S. Huisman, Kim Philipp Jablonski, Lara Fuhrmann, David Dreifuss, Katharina Jahn, Christiane Beckmann, Maurice Redondo, Christoph Noppen, Lorenz Risch, Martin Risch, Nadia Wohlwend, Sinem Kas, Thomas Bodmer, Tim Roloff, Madlen Stange, Adrian Egli, Isabella Eckerle, Laurent Kaiser, Rebecca Denes, Mirjam Feldkamp, Ina Nissen, Natascha Santacroce, Elodie Burcklen, Catharine Aquino, Andreia Cabral de Gouvea, Maria Domenica Moccia, Simon Grüter, Timothy Sykes, Lennart Opitz, Griffin White, Laura Neff, Doris Popovic, Andrea Patrignani, Jay Tracy, Ralph Schlapbach, Emmanouil T. Dermitzakis, Keith Harshman, Ioannis Xenarios, Henri Pegeot, Lorenzo Cerutti, Deborah Penet, Anthony Blin, Melyssa Elies, Christian L. Althaus, Christian Beisel, Niko Beerenwinkel, Martin Ackermann, Tanja Stadler
Format: Article
Language:English
Published: Elsevier 2021-12-01
Series:Epidemics
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S1755436521000335
id doaj-bd41319829ad4201b8f18a7bf5efe47f
record_format Article
collection DOAJ
language English
format Article
sources DOAJ
author Chaoran Chen
Sarah Ann Nadeau
Ivan Topolsky
Marc Manceau
Jana S. Huisman
Kim Philipp Jablonski
Lara Fuhrmann
David Dreifuss
Katharina Jahn
Christiane Beckmann
Maurice Redondo
Christoph Noppen
Lorenz Risch
Martin Risch
Nadia Wohlwend
Sinem Kas
Thomas Bodmer
Tim Roloff
Madlen Stange
Adrian Egli
Isabella Eckerle
Laurent Kaiser
Rebecca Denes
Mirjam Feldkamp
Ina Nissen
Natascha Santacroce
Elodie Burcklen
Catharine Aquino
Andreia Cabral de Gouvea
Maria Domenica Moccia
Simon Grüter
Timothy Sykes
Lennart Opitz
Griffin White
Laura Neff
Doris Popovic
Andrea Patrignani
Jay Tracy
Ralph Schlapbach
Emmanouil T. Dermitzakis
Keith Harshman
Ioannis Xenarios
Henri Pegeot
Lorenzo Cerutti
Deborah Penet
Anthony Blin
Melyssa Elies
Christian L. Althaus
Christian Beisel
Niko Beerenwinkel
Martin Ackermann
Tanja Stadler
spellingShingle Chaoran Chen
Sarah Ann Nadeau
Ivan Topolsky
Marc Manceau
Jana S. Huisman
Kim Philipp Jablonski
Lara Fuhrmann
David Dreifuss
Katharina Jahn
Christiane Beckmann
Maurice Redondo
Christoph Noppen
Lorenz Risch
Martin Risch
Nadia Wohlwend
Sinem Kas
Thomas Bodmer
Tim Roloff
Madlen Stange
Adrian Egli
Isabella Eckerle
Laurent Kaiser
Rebecca Denes
Mirjam Feldkamp
Ina Nissen
Natascha Santacroce
Elodie Burcklen
Catharine Aquino
Andreia Cabral de Gouvea
Maria Domenica Moccia
Simon Grüter
Timothy Sykes
Lennart Opitz
Griffin White
Laura Neff
Doris Popovic
Andrea Patrignani
Jay Tracy
Ralph Schlapbach
Emmanouil T. Dermitzakis
Keith Harshman
Ioannis Xenarios
Henri Pegeot
Lorenzo Cerutti
Deborah Penet
Anthony Blin
Melyssa Elies
Christian L. Althaus
Christian Beisel
Niko Beerenwinkel
Martin Ackermann
Tanja Stadler
Quantification of the spread of SARS-CoV-2 variant B.1.1.7 in Switzerland
Epidemics
Pandemic
SARS-CoV-2
COVID-19
B.1.1.7
Transmission advantage
author_facet Chaoran Chen
Sarah Ann Nadeau
Ivan Topolsky
Marc Manceau
Jana S. Huisman
Kim Philipp Jablonski
Lara Fuhrmann
David Dreifuss
Katharina Jahn
Christiane Beckmann
Maurice Redondo
Christoph Noppen
Lorenz Risch
Martin Risch
Nadia Wohlwend
Sinem Kas
Thomas Bodmer
Tim Roloff
Madlen Stange
Adrian Egli
Isabella Eckerle
Laurent Kaiser
Rebecca Denes
Mirjam Feldkamp
Ina Nissen
Natascha Santacroce
Elodie Burcklen
Catharine Aquino
Andreia Cabral de Gouvea
Maria Domenica Moccia
Simon Grüter
Timothy Sykes
Lennart Opitz
Griffin White
Laura Neff
Doris Popovic
Andrea Patrignani
Jay Tracy
Ralph Schlapbach
Emmanouil T. Dermitzakis
Keith Harshman
Ioannis Xenarios
Henri Pegeot
Lorenzo Cerutti
Deborah Penet
Anthony Blin
Melyssa Elies
Christian L. Althaus
Christian Beisel
Niko Beerenwinkel
Martin Ackermann
Tanja Stadler
author_sort Chaoran Chen
title Quantification of the spread of SARS-CoV-2 variant B.1.1.7 in Switzerland
title_short Quantification of the spread of SARS-CoV-2 variant B.1.1.7 in Switzerland
title_full Quantification of the spread of SARS-CoV-2 variant B.1.1.7 in Switzerland
title_fullStr Quantification of the spread of SARS-CoV-2 variant B.1.1.7 in Switzerland
title_full_unstemmed Quantification of the spread of SARS-CoV-2 variant B.1.1.7 in Switzerland
title_sort quantification of the spread of sars-cov-2 variant b.1.1.7 in switzerland
publisher Elsevier
series Epidemics
issn 1755-4365
publishDate 2021-12-01
description Background: In December 2020, the United Kingdom (UK) reported a SARS-CoV-2 Variant of Concern (VoC) which is now named B.1.1.7. Based on initial data from the UK and later data from other countries, this variant was estimated to have a transmission fitness advantage of around 40–80 % (Volz et al., 2021; Leung et al., 2021; Davies et al., 2021). Aim: This study aims to estimate the transmission fitness advantage and the effective reproductive number of B.1.1.7 through time based on data from Switzerland. Methods: We generated whole genome sequences from 11.8 % of all confirmed SARS-CoV-2 cases in Switzerland between 14 December 2020 and 11 March 2021. Based on these data, we determine the daily frequency of the B.1.1.7 variant and quantify the variant’s transmission fitness advantage on a national and a regional scale. Results: We estimate B.1.1.7 had a transmission fitness advantage of 43–52 % compared to the other variants circulating in Switzerland during the study period. Further, we estimate B.1.1.7 had a reproductive number above 1 from 01 January 2021 until the end of the study period, compared to below 1 for the other variants. Specifically, we estimate the reproductive number for B.1.1.7 was 1.24 [1.07–1.41] from 01 January until 17 January 2021 and 1.18 [1.06–1.30] from 18 January until 01 March 2021 based on the whole genome sequencing data. From 10 March to 16 March 2021, once B.1.1.7 was dominant, we estimate the reproductive number was 1.14 [1.00–1.26] based on all confirmed cases. For reference, Switzerland applied more non-pharmaceutical interventions to combat SARS-CoV-2 on 18 January 2021 and lifted some measures again on 01 March 2021. Conclusion: The observed increase in B.1.1.7 frequency in Switzerland during the study period is as expected based on observations in the UK. In absolute numbers, B.1.1.7 increased exponentially with an estimated doubling time of around 2–3.5 weeks. To monitor the ongoing spread of B.1.1.7, our plots are available online.
topic Pandemic
SARS-CoV-2
COVID-19
B.1.1.7
Transmission advantage
url http://www.sciencedirect.com/science/article/pii/S1755436521000335
work_keys_str_mv AT chaoranchen quantificationofthespreadofsarscov2variantb117inswitzerland
AT sarahannnadeau quantificationofthespreadofsarscov2variantb117inswitzerland
AT ivantopolsky quantificationofthespreadofsarscov2variantb117inswitzerland
AT marcmanceau quantificationofthespreadofsarscov2variantb117inswitzerland
AT janashuisman quantificationofthespreadofsarscov2variantb117inswitzerland
AT kimphilippjablonski quantificationofthespreadofsarscov2variantb117inswitzerland
AT larafuhrmann quantificationofthespreadofsarscov2variantb117inswitzerland
AT daviddreifuss quantificationofthespreadofsarscov2variantb117inswitzerland
AT katharinajahn quantificationofthespreadofsarscov2variantb117inswitzerland
AT christianebeckmann quantificationofthespreadofsarscov2variantb117inswitzerland
AT mauriceredondo quantificationofthespreadofsarscov2variantb117inswitzerland
AT christophnoppen quantificationofthespreadofsarscov2variantb117inswitzerland
AT lorenzrisch quantificationofthespreadofsarscov2variantb117inswitzerland
AT martinrisch quantificationofthespreadofsarscov2variantb117inswitzerland
AT nadiawohlwend quantificationofthespreadofsarscov2variantb117inswitzerland
AT sinemkas quantificationofthespreadofsarscov2variantb117inswitzerland
AT thomasbodmer quantificationofthespreadofsarscov2variantb117inswitzerland
AT timroloff quantificationofthespreadofsarscov2variantb117inswitzerland
AT madlenstange quantificationofthespreadofsarscov2variantb117inswitzerland
AT adrianegli quantificationofthespreadofsarscov2variantb117inswitzerland
AT isabellaeckerle quantificationofthespreadofsarscov2variantb117inswitzerland
AT laurentkaiser quantificationofthespreadofsarscov2variantb117inswitzerland
AT rebeccadenes quantificationofthespreadofsarscov2variantb117inswitzerland
AT mirjamfeldkamp quantificationofthespreadofsarscov2variantb117inswitzerland
AT inanissen quantificationofthespreadofsarscov2variantb117inswitzerland
AT nataschasantacroce quantificationofthespreadofsarscov2variantb117inswitzerland
AT elodieburcklen quantificationofthespreadofsarscov2variantb117inswitzerland
AT catharineaquino quantificationofthespreadofsarscov2variantb117inswitzerland
AT andreiacabraldegouvea quantificationofthespreadofsarscov2variantb117inswitzerland
AT mariadomenicamoccia quantificationofthespreadofsarscov2variantb117inswitzerland
AT simongruter quantificationofthespreadofsarscov2variantb117inswitzerland
AT timothysykes quantificationofthespreadofsarscov2variantb117inswitzerland
AT lennartopitz quantificationofthespreadofsarscov2variantb117inswitzerland
AT griffinwhite quantificationofthespreadofsarscov2variantb117inswitzerland
AT lauraneff quantificationofthespreadofsarscov2variantb117inswitzerland
AT dorispopovic quantificationofthespreadofsarscov2variantb117inswitzerland
AT andreapatrignani quantificationofthespreadofsarscov2variantb117inswitzerland
AT jaytracy quantificationofthespreadofsarscov2variantb117inswitzerland
AT ralphschlapbach quantificationofthespreadofsarscov2variantb117inswitzerland
AT emmanouiltdermitzakis quantificationofthespreadofsarscov2variantb117inswitzerland
AT keithharshman quantificationofthespreadofsarscov2variantb117inswitzerland
AT ioannisxenarios quantificationofthespreadofsarscov2variantb117inswitzerland
AT henripegeot quantificationofthespreadofsarscov2variantb117inswitzerland
AT lorenzocerutti quantificationofthespreadofsarscov2variantb117inswitzerland
AT deborahpenet quantificationofthespreadofsarscov2variantb117inswitzerland
AT anthonyblin quantificationofthespreadofsarscov2variantb117inswitzerland
AT melyssaelies quantificationofthespreadofsarscov2variantb117inswitzerland
AT christianlalthaus quantificationofthespreadofsarscov2variantb117inswitzerland
AT christianbeisel quantificationofthespreadofsarscov2variantb117inswitzerland
AT nikobeerenwinkel quantificationofthespreadofsarscov2variantb117inswitzerland
AT martinackermann quantificationofthespreadofsarscov2variantb117inswitzerland
AT tanjastadler quantificationofthespreadofsarscov2variantb117inswitzerland
_version_ 1717814600483733504
spelling doaj-bd41319829ad4201b8f18a7bf5efe47f2021-09-05T04:40:04ZengElsevierEpidemics1755-43652021-12-0137100480Quantification of the spread of SARS-CoV-2 variant B.1.1.7 in SwitzerlandChaoran Chen0Sarah Ann Nadeau1Ivan Topolsky2Marc Manceau3Jana S. Huisman4Kim Philipp Jablonski5Lara Fuhrmann6David Dreifuss7Katharina Jahn8Christiane Beckmann9Maurice Redondo10Christoph Noppen11Lorenz Risch12Martin Risch13Nadia Wohlwend14Sinem Kas15Thomas Bodmer16Tim Roloff17Madlen Stange18Adrian Egli19Isabella Eckerle20Laurent Kaiser21Rebecca Denes22Mirjam Feldkamp23Ina Nissen24Natascha Santacroce25Elodie Burcklen26Catharine Aquino27Andreia Cabral de Gouvea28Maria Domenica Moccia29Simon Grüter30Timothy Sykes31Lennart Opitz32Griffin White33Laura Neff34Doris Popovic35Andrea Patrignani36Jay Tracy37Ralph Schlapbach38Emmanouil T. Dermitzakis39Keith Harshman40Ioannis Xenarios41Henri Pegeot42Lorenzo Cerutti43Deborah Penet44Anthony Blin45Melyssa Elies46Christian L. Althaus47Christian Beisel48Niko Beerenwinkel49Martin Ackermann50Tanja Stadler51Department of Biosystems Science and Engineering, ETH Zürich, Basel, Switzerland; Swiss Institute of Bioinformatics, SwitzerlandDepartment of Biosystems Science and Engineering, ETH Zürich, Basel, Switzerland; Swiss Institute of Bioinformatics, SwitzerlandDepartment of Biosystems Science and Engineering, ETH Zürich, Basel, Switzerland; Swiss Institute of Bioinformatics, SwitzerlandDepartment of Biosystems Science and Engineering, ETH Zürich, Basel, Switzerland; Swiss Institute of Bioinformatics, SwitzerlandDepartment of Biosystems Science and Engineering, ETH Zürich, Basel, Switzerland; Swiss Institute of Bioinformatics, Switzerland; Department of Environmental Systems Science, ETH Zürich, Swiss Federal Institute of Technology, Zurich, SwitzerlandDepartment of Biosystems Science and Engineering, ETH Zürich, Basel, Switzerland; Swiss Institute of Bioinformatics, SwitzerlandDepartment of Biosystems Science and Engineering, ETH Zürich, Basel, Switzerland; Swiss Institute of Bioinformatics, SwitzerlandDepartment of Biosystems Science and Engineering, ETH Zürich, Basel, Switzerland; Swiss Institute of Bioinformatics, SwitzerlandDepartment of Biosystems Science and Engineering, ETH Zürich, Basel, Switzerland; Swiss Institute of Bioinformatics, SwitzerlandViollier AG, Allschwil, SwitzerlandViollier AG, Allschwil, SwitzerlandViollier AG, Allschwil, SwitzerlandDr Risch, Labormedizinisches Zentrum, SwitzerlandDr Risch, Labormedizinisches Zentrum, SwitzerlandDr Risch, Labormedizinisches Zentrum, SwitzerlandDr Risch, Labormedizinisches Zentrum, SwitzerlandDr Risch, Labormedizinisches Zentrum, SwitzerlandSwiss Institute of Bioinformatics, Switzerland; Clinical Bacteriology and Mycology, University Hospital Basel, Basel, Switzerland; Applied Microbiology Research, Department of Biomedicine, University of Basel, Basel, SwitzerlandSwiss Institute of Bioinformatics, Switzerland; Clinical Bacteriology and Mycology, University Hospital Basel, Basel, Switzerland; Applied Microbiology Research, Department of Biomedicine, University of Basel, Basel, SwitzerlandClinical Bacteriology and Mycology, University Hospital Basel, Basel, Switzerland; Applied Microbiology Research, Department of Biomedicine, University of Basel, Basel, SwitzerlandGeneva Center for Emerging Viral Diseases and Laboratory of Virology, Geneva University Hospitals, Geneva, Switzerland; Department of Microbiology and Molecular Medicine, Faculty of Medicine, University of Geneva, Geneva, SwitzerlandGeneva Center for Emerging Viral Diseases and Laboratory of Virology, Geneva University Hospitals, Geneva, Switzerland; Division of Infectious Diseases, Geneva University Hospitals, Geneva, Switzerland; Department of Medicine, Faculty of Medicine, University of Geneva, Geneva, SwitzerlandGenomic Facility Basel, Department of Biosystems Science and Engineering, ETH Zürich, Basel, SwitzerlandGenomic Facility Basel, Department of Biosystems Science and Engineering, ETH Zürich, Basel, SwitzerlandGenomic Facility Basel, Department of Biosystems Science and Engineering, ETH Zürich, Basel, SwitzerlandGenomic Facility Basel, Department of Biosystems Science and Engineering, ETH Zürich, Basel, SwitzerlandGenomic Facility Basel, Department of Biosystems Science and Engineering, ETH Zürich, Basel, SwitzerlandFunctional Genomics Center Zurich, ETH Zürich and University of Zurich, Zurich, SwitzerlandFunctional Genomics Center Zurich, ETH Zürich and University of Zurich, Zurich, SwitzerlandFunctional Genomics Center Zurich, ETH Zürich and University of Zurich, Zurich, SwitzerlandFunctional Genomics Center Zurich, ETH Zürich and University of Zurich, Zurich, SwitzerlandFunctional Genomics Center Zurich, ETH Zürich and University of Zurich, Zurich, SwitzerlandFunctional Genomics Center Zurich, ETH Zürich and University of Zurich, Zurich, SwitzerlandFunctional Genomics Center Zurich, ETH Zürich and University of Zurich, Zurich, SwitzerlandFunctional Genomics Center Zurich, ETH Zürich and University of Zurich, Zurich, SwitzerlandFunctional Genomics Center Zurich, ETH Zürich and University of Zurich, Zurich, SwitzerlandFunctional Genomics Center Zurich, ETH Zürich and University of Zurich, Zurich, SwitzerlandFunctional Genomics Center Zurich, ETH Zürich and University of Zurich, Zurich, SwitzerlandFunctional Genomics Center Zurich, ETH Zürich and University of Zurich, Zurich, SwitzerlandHealth 2030 Genome Center, Geneva, Switzerland; University of Geneva Medical School, Geneva, SwitzerlandHealth 2030 Genome Center, Geneva, Switzerland; Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland; Department of Environmental Microbiology, Eawag, Dubendorf, SwitzerlandHealth 2030 Genome Center, Geneva, Switzerland; University of Geneva Medical School, Geneva, SwitzerlandHealth 2030 Genome Center, Geneva, SwitzerlandHealth 2030 Genome Center, Geneva, SwitzerlandHealth 2030 Genome Center, Geneva, SwitzerlandHealth 2030 Genome Center, Geneva, SwitzerlandHealth 2030 Genome Center, Geneva, SwitzerlandInstitute of Social and Preventive Medicine, University of Bern, Bern, SwitzerlandDepartment of Biosystems Science and Engineering, ETH Zürich, Basel, SwitzerlandDepartment of Biosystems Science and Engineering, ETH Zürich, Basel, Switzerland; Swiss Institute of Bioinformatics, SwitzerlandDepartment of Environmental Systems Science, ETH Zürich, Swiss Federal Institute of Technology, Zurich, Switzerland; Department of Environmental Microbiology, Eawag, Dubendorf, SwitzerlandDepartment of Biosystems Science and Engineering, ETH Zürich, Basel, Switzerland; Swiss Institute of Bioinformatics, Switzerland; Corresponding author at: Department of Biosystems Science and Engineering, ETH Zürich, Basel, Switzerland.Background: In December 2020, the United Kingdom (UK) reported a SARS-CoV-2 Variant of Concern (VoC) which is now named B.1.1.7. Based on initial data from the UK and later data from other countries, this variant was estimated to have a transmission fitness advantage of around 40–80 % (Volz et al., 2021; Leung et al., 2021; Davies et al., 2021). Aim: This study aims to estimate the transmission fitness advantage and the effective reproductive number of B.1.1.7 through time based on data from Switzerland. Methods: We generated whole genome sequences from 11.8 % of all confirmed SARS-CoV-2 cases in Switzerland between 14 December 2020 and 11 March 2021. Based on these data, we determine the daily frequency of the B.1.1.7 variant and quantify the variant’s transmission fitness advantage on a national and a regional scale. Results: We estimate B.1.1.7 had a transmission fitness advantage of 43–52 % compared to the other variants circulating in Switzerland during the study period. Further, we estimate B.1.1.7 had a reproductive number above 1 from 01 January 2021 until the end of the study period, compared to below 1 for the other variants. Specifically, we estimate the reproductive number for B.1.1.7 was 1.24 [1.07–1.41] from 01 January until 17 January 2021 and 1.18 [1.06–1.30] from 18 January until 01 March 2021 based on the whole genome sequencing data. From 10 March to 16 March 2021, once B.1.1.7 was dominant, we estimate the reproductive number was 1.14 [1.00–1.26] based on all confirmed cases. For reference, Switzerland applied more non-pharmaceutical interventions to combat SARS-CoV-2 on 18 January 2021 and lifted some measures again on 01 March 2021. Conclusion: The observed increase in B.1.1.7 frequency in Switzerland during the study period is as expected based on observations in the UK. In absolute numbers, B.1.1.7 increased exponentially with an estimated doubling time of around 2–3.5 weeks. To monitor the ongoing spread of B.1.1.7, our plots are available online.http://www.sciencedirect.com/science/article/pii/S1755436521000335PandemicSARS-CoV-2COVID-19B.1.1.7Transmission advantage